{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:27:49Z","timestamp":1787740069135,"version":"build-2784847793"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaip.2024.03.049","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:09:04Z","timestamp":1712329744000},"page":"1794-1800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5\/5R Therapy in Severe Eosinophilic Asthma"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7777-0201","authenticated-orcid":false,"given":"Jessica","family":"Gates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hearn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cris","family":"Roxas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grainne","family":"d\u2019Ancona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M.","family":"Nanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Dhariwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.03.049_bib1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.03.049_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.03.049_bib3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.03.049_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0144-2021","article-title":"A\u00a0pragmatic guide to choosing biologic therapies in severe asthma","volume":"17","author":"Kavanagh","year":"2021","journal-title":"Breathe"},{"key":"10.1016\/j.jaip.2024.03.049_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coi.2020.10.004","article-title":"Biologic treatment options for severe asthma","volume":"66","author":"Hearn","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaip.2024.03.049_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \u201csuper-responder\u201d to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.03.049_bib7","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/all.14693","article-title":"Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma","volume":"76","author":"Kavanagh","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2024.03.049_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.03.049_bib9","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.03.049_bib10","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.03.049_bib13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying anti-asthmatic drugs","volume":"399","author":"Lommatzsch","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2024.03.049_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaip.2020.09.014","article-title":"Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy","volume":"9","author":"M\u00fcmmler","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.03.049_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaip.2024.03.049_bib16","doi-asserted-by":"crossref","first-page":"P271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982400343X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982400343X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:27:07Z","timestamp":1730521627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321982400343X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S221321982400343X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.03.049","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Effectiveness of Anti-IL-4R Therapy Following Suboptimal Response to Anti-IL-5\/5R Therapy in Severe Eosinophilic Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.03.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}